DAFTAR PUSTAKA

1. Katno, Pramono S. Tingkat Manfaat dan Keamanan Tanaman Obat dan Obat
Tradisional. Balai Penelitian Obat Tawangmangu, Fakultas Farmasi
Universitas Gajah Mada [press release]. Yogyakarta: Fakultas Farmasi UGM.
2. Faried A, Kurnia D, Faried L.S, Usman N, T. Miyazaki, Kato H. Anticancer
effects of gallic acid isolated from Indonesian herbal medicine, Phaleria
macrocarpa (Scheff.) Boerl, on human cancer cell lines. Int j oncol [Internet].
2007 [cited 2012 Nov 29];30(3): 605-13. Available from: Spandidos
Publications
3. Amit KT, Madhumita R, Bhattacharya RK. Natural products as inducers of
apoptosis: Implication for cancer therapy and prevention. Current Science
[Internet]. 2001 [cited 2012 Nov 29]; 80(11):1387-96. Available from: Indian
Institute of Science
4. Tazulakhova EB, Parshina OV, Guseva TS, Ershov FI. Russian experience
screening, analysis, and clinical application of novel interferon inducers. J
Interferon Cytokine Res [Internet]. 2001 [cited 2012 Nov 29]; 21(2): 65-73.
Available from: Marry Ann Liebert Inc. publisher
5. Stagg J. Phyllanthus. c2006 [updated 2006 Jun 17; cited 2013 Feb 7].
Available from: http://www.supplementnews.org/phyllanthus.html cited
17/6/06
6. Williams JE. Review of antiviral and immunomodulating properties of plants
of the Peruvian rainforest with a particular emphasis on Uña de Gato and
Sangre de Grando. Alternative Medicine Review [Internet]. 2001 [cited 2012
Nov 29];6(6):567-79. Available from: Thorne Research, Inc.
7. Ahmed N, Agrawal SS, Chattervedi S, Tabassum N. Hepatoprotective studies
on phyllanthus niruri on paracetamol induced liver cell damage in albino

55
 56

mice. JK-Practtitioner [Internet]. 2005 [cited 2012 Nov 29]; 12(4):211-2.

Available from: Indian Medlars Centre
8. Bagalkotkar G, Sagineedu SR, Saad MS, Stanslas. Phytochemicals from
phyllanthus niruri linn and their pharmacological properties. Journal of
Pharmacy and Pharmacology [Internet]. 2006 [cited 2012 Nov 29]; 58(12):
1559-70. Available from: Wiley Online Library
9. Phyllanthus Introduction [Internet]. c2009 [updated 2009 Jun 2; cited 2012
Nov 29]. Available from: http://www.supplementnews.org/wiki/phyllanthus
10. Krithika R, Mohankumar R, Verma RJ. Shrivastav PS, Mohamad IL,
Gunasekaran P, et al. Isolation, characterization and antioxidative effect of
phyllanthin against CCl4-induced toxicity in HepG2 cell line. Chemico-
Biological Interactions Journal [Internet]. 2009 [cited 2012 Nov 29]; 181(3):
351-8. Available from: ScienceDirect
11. Setiawati A, Suyatna FD, Gan S. Pengantar Farmakologi dan Terapi. 5th ed.
Jakarta: Departemen Farmakologi dan Terapeutik Fakultas Kedokteran
Universitas Indonesia; 2007.
12. Donatus IA. Toksikologi Dasar. 2nd ed. Yogyakarta: Bagian Farmakologi dan
Farmasi Klinik Fakultas Farmasi Universitas Gajah Mada; 2005
13. Mehta N, Ozick LA, Gbadehan E, Sharma S, Tavalera F, Rice TD, et al.
Drug-Induced Hepatotoxicity [Internet]. c2012 [updated 2012 Jun 27; cited
2012 Nov 29]. Available from:
http://emedicine.medscape.com/article/169814-overview#aw2aab6b4
14. Katzung BG. Farmakologi Dasar dan Klinik. 10th ed. Jakarta: Penerbit Buku
Kedokteran EGC; 2010
15. Underwood JC, Cross SS. General and Systematic Pathology. 5th ed. London:
Churcill Livingstone; 2009
16. Kumar V, Cotran RS, Robbins SL. Buku Ajar Patologi. 7th ed. Jakarta:
Penerbit Buku Kedokteran EGC; 2007
 57

17. Guyton AC, Hall JE. Buku Ajar Fisiologi Kedokteran. 11th ed. Jakarta: EGC;
2007. 902-6
18. Moslen, MT. Toxic responses of the liver. In: Klaasen, CD, Editor. Casarett
and Doull’s toxicology the basic science of poisons. 6th ed. New York: Mac
Graw Hill; 2001. 471-88
19. Parkinson A. Biotransformation of xenobiotics. In: Klaasen, CD, Editor.
Casarett and Doull’s toxicology the basic science of poisons. 6th ed. New
York: Mac Graw Hill; 2001. 72-97
20. Patient UK. Liver Function Test [Internet]. c2010 [updated 2010 Feb 02, cited
2013 Jan 26]. Available from: http://www.patient.co.uk/health/Blood-Test-
Liver-Function-Tests.htm
21. Herrine KS, Navarro VJ. Liver Injury Caused by Drugs [Internet]. c2009
[updated 2013 Jan, cited 2013 Jan 26]. Available from:
http://www.merck.com/mmpe/sec03/ch024/ch024c.html
22. Liver function test. Wikipedia [online] c2009 [updated 2009 Oct 07, cited
2013 Jan 26] Available from: http://en.wikipedia.org/wiki/liver_function_test
23. Tim Penulis. Buku Ajar Ilmu Penyakit Dalam Jilid I. 3rd ed cetakan ke-7.
Jakarta: Balai Penerbit FKUI; 2004. 226-7
24. Guyton AC, Hall JE. Buku Ajar Fisiologi Kedokteran. 11th ed. Jakarta: EGC;
2007. 324-33
25. Schnellmann RG. Toxic responses of the kidney. In: Klassen CD. Casarett
and Doull’s toxicology the basic science of poisons. 6th ed. New York: Mac
Graw Hill; 2001. 491-510
26. Hodgson E, Levi PE. Nephrotoxicity. In: Hodgson E, editor. A Textbook of
modern toxicology, 3rd ed. New York: John Wiley & Sons; 2004. 273-5
27. Cotran RS. Ginjal dan sistem penyalurannya. In: Robbins SL, Kumar V. Staf
Pengajar Laboratorium Patologi Anatomik Fakultas Kedokteran Universitas
Airlangga, editor. Buku ajar patologi II. 4th ed. Jakarta: EGC; 1995. 203-4
 58

28. Underwood JCE. Sarjadi, editor. Patologi umum dan sistemik. 2nd ed. Jakarta:
EGC; 2000
29. Ford-Martin PA, Best MA. Kidney Function Tests [Internet]. cited 2013 Jan
26. Available from: http://www.surgeryencyclopedia.com/Fi-La/Kidney-
Function-Tests.html
30. Tim Penulis. Buku Ajar Ilmu Penyakit Dalam Jilid II. 3rd ed cetakan ke-2.
Jakarta: Balai Penerbit FKUI; 2004. 301
31. Lisdawati V. Mahkota Dewa, toksisitas, efek anti oksidan, dan efek anti-
kanker berdasarkan uji penapisan farmakologi [Internet]. c2002 [updated 2004
Jul 09, cited 2013 Jan 26]. Available from:
http://mahkotadewa.com/blog/2004/07/tinjauan-ilmiah-dra-vivi-lisdawati-
msi-apt/
32. Sumastuti R, Sonlimar M. Efek sitotoksik ekstrak buah dan daun Mahkota
Dewa terhadap sel hela. Yogyakarta: Farmakologi FK UGM; 2003
33. Selamat B, Benny I, Djoko H, Dwi P, Riwanto I. Pengaruh kombinasi ekstrak
mahkota dewa (phaleria macrocarpa) dengan doxorubicin dan
cyclophosphamide terhadap ekspresi VEGF dan indeks apoptosis tumor
adenokarsinoma mamma mencit C3H. (in-press).
34. Sulaksana J, Jayusman DI. Meniran, Budi Daya dan Pemanfaatan untuk Obat.
Cetakan I, Jakarta: Penebar Swadaya; 2004.
35. Taylor. Technical Data Report for Chanca Piedra. In: Herbal Secrets of The
Rainforest, 2nd ed, Austin India: Sage Press, Inc; 2003
36. Mangan Y. Cara Bijak Menaklukkan Kanker. Sehat dengan Ramuan
Tradisional. Cetakan keempat revisi, Jakarta: Agro Media Pustaka; 2005.
37. Markom M, Hasan M, Daud WRW, Singh H, Jahim JM. Extraction of
hydrolisable tannins from Phyllanthus niruri Linn: effects of solvents and
extraction methods. Separation and Purification Technology [Internet]. 2007
[cited 2013 Jan 26]; 52(3): 487-96. Available from: ScienceDirect
 59

38. Liu L, Lin H. Genus Phyllanthus for chronic hepatitis B virus infection. J
Viral Hepatitis [Internet]. 2001 [cited 2013 Jan 26]; 8(5): 358-62. Available
from: Wiley Online Library
39. Mustofa, Solikhah EN, Wahyuono S. In vitro and in vivo antiplasmodial
activity and cytotoxicity of extracts of Phyllanthus niruri Linn herbs
traditionally used to treat malaria in Indonesia. Southeast Asian J. Trop Med
Public Health [Internet]. 2007 [cited 2013 Jan 26]; 38(4): 609-15. Available
from: Index Medicus for South-East Asia Region
40. Taylor, L. Chanca Piedra. In: The Healing Power of Rainforest Herb. Carson
City: Raintree Nutrition, Inc; 2005
41. Ma’at S. Imunomodulator manfaat dan bahayanya. Dalam: Kusmita L,
Djatmika. Imunomodulator dan Perkembangannya. Prosiding Seminar
Nasional Farmasi Tahun 2010 Cetakan ketiga. Semarang: Penerbit STIFAR
Yayasan Farmasi; 2010
42. Sumaryanto W. Analisis Urea-Kreatinin Tikus Putih pasca Pemberian Ekstrak
Buah Mahkota Dewa dan Herba Pegagan. Jurnal Ilmu Kefarmasian Indonesia.
2008; 6(1): 35-40
43. Edhiatmi M. Pengaruh Pemberian Ekstrak Mahkota Dewa (Phaleria
papuana) Dosis Bertingkat terhadap Struktur Histologik Hepar Mencit
BALB/c. Semarang: Program Studi Pendidikan Kedokteran Universitas
Diponegoro;2006
44. Firdaus GI. Uji Toksisitas Akut Ekstrak Meniran (Phyllanthus niruri)
terhadap Hepar Mencit BALB/c. Semarang: Program Studi Pendidikan
Kedokteran Universitas Diponegoro; 2010
45. Alboneh SFH. Uji Toksisitas Akut Ekstrak Meniran (Phyllanthus niruri)
terhadap Ginjal Mencit BALB/c. Semarang: Program Studi Pendidikan
Kedokteran Universitas Diponegoro; 2010
46. Ali RB, Atangwho IJ, Kaur N, Abraika OS, Ahmad M, Mahmud R, et al.
Bioassay-guided antidiabetic study of Phaleria macrocarpa fruit extract.
 60

Molecules [Internet]. 2012 [cited 2013 July 22]; 17(5): 4986-5002. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/22547320
47. Gordon WP, Forte AJ, McMurtry RJ, Gal J. Hepatotoxicity and pulmonary
toxicity of pennyroyal oil and its constituent terpenes in the mouse.
Toxicology and Applied Pharmacology [Internet]. 1982 [cited 2013 July 22];
65(3): 413-24. Available from:
http://www.sciencedirect.com/science/article/pii/0041008X82903878
48. Authors. Terpenes. TCI America. Available from:
http://www.tcichemicals.com/eshop/en/us/category_index/00306/
 61

DOKUMENTASI PENELITIAN
 62

OUTPUT ANALISIS SPSS 11.5 FOR WINDOWS

1. Kadar AST

Tabel 4. Kadar AST

Sampel Kontrol P1 P2 P3
A 269 425 152 263
B 209 767 200 231
C 299 279 196 227
D 260 190 165 348
E 452 231 185 222
Rata- 297,8 378,4 179,6 258,2
rata

a. Analisis Deskriptif
Descriptives

PERLAKUA Statistic Std. Error

KADAR K Mean 297,80 41,184
95% Confidence Lower Bound
183,45
Interval for Mean
Upper Bound
412,15
5% Trimmed Mean 294,17
Median 269,00
Variance 8480,700
Std. Deviation 92,091
Minimum 209
Maximum 452
Range 243
Interquartile Range 141,00
Skewness 1,541 ,913
Kurtosis 2,954 2,000
P1 Mean 378,40 104,948
95% Confidence Lower Bound
87,02
Interval for Mean
Upper Bound
669,78
5% Trimmed Mean 367,28
 63

Median 279,00
Variance 55070,80
0
Std. Deviation 234,672
Minimum 190
Maximum 767
Range 577
Interquartile Range 385,50
Skewness 1,545 ,913
Kurtosis 2,155 2,000
P2 Mean 179,60 9,190
95% Confidence Lower Bound
154,08
Interval for Mean
Upper Bound
205,12
5% Trimmed Mean 180,00
Median 185,00
Variance 422,300
Std. Deviation 20,550
Minimum 152
Maximum 200
Range 48
Interquartile Range 39,50
Skewness -,532 ,913
Kurtosis -1,887 2,000
P3 Mean 258,20 23,570
95% Confidence Lower Bound
192,76
Interval for Mean
Upper Bound
323,64
5% Trimmed Mean 255,22
Median 231,00
Variance 2777,700
Std. Deviation 52,704
Minimum 222
Maximum 348
Range 126
Interquartile Range 81,00
Skewness 1,783 ,913
Kurtosis 3,056 2,000

b. Analisis Analitik

1). Uji Normalitas

 64

Tests of Normality
a
Kolmogorov -Smirnov Shapiro-Wilk
PERLAKUA St at ist ic df Sig. St at ist ic df Sig.
KADAR K ,295 5 ,179 ,861 5 ,233
P1 ,264 5 ,200* ,841 5 ,167
P2 ,204 5 ,200* ,918 5 ,519
P3 ,297 5 ,171 ,769 5 ,044
*. This is a lower bound of the true signif icance.
a. Lillief ors Signif icance Correction

2). Uji Normalitas Setelah Data Ditransform dengan log-n

Tests of Normality
a
Kolmogorov -Smirnov Shapiro-Wilk
PERLAKUA St at ist ic df Sig. St at ist ic df Sig.
TRANS K ,247 5 ,200* ,926 5 ,568
P1 ,221 5 ,200* ,935 5 ,629
P2 ,217 5 ,200* ,912 5 ,482
P3 ,297 5 ,172 ,798 5 ,077
*. This is a lower bound of the true signif icance.
a. Lillief ors Signif icance Correction

3). Uji One Way ANOVA

ANOVA

TRANS
Sum of
Squares df Mean Square F Sig.
Between Groups ,198 3 ,066 3,191 ,052
Within Groups ,331 16 ,021
Total ,528 19
 65

2. Kadar ALT

Tabel 6. Kadar ALT

Sampel Kontrol P1 P2 P3
A 81 123 57 83
B 63 249 65 65
C 85 74 112 60
D 134 52 79 87
E 128 43 108 94
Rata- 98,2 108,2 84,2 77,8
rata

a. Analisis Deskriptif
Descriptives

PERLAKUA Statistic Std. Error

KADAR K Mean 98,20 13,926
95% Confidence Interval Lower Bound
59,53
for Mean
Upper Bound
136,87

5% Trimmed Mean 98,17

Median 85,00
Variance 969,700
Std. Deviation 31,140
Minimum 63
Maximum 134
Range 71
Interquartile Range 59,00
Skewness ,295 ,913
Kurtosis -2,571 2,000
P1 Mean 108,20 37,830
95% Confidence Interval Lower Bound
3,17
for Mean
Upper Bound
213,23

5% Trimmed Mean 104,00

Median 74,00
Variance 7155,700
Std. Deviation 84,591
 66

Minimum 43
Maximum 249
Range 206
Interquartile Range 138,50
Skewness 1,583 ,913
Kurtosis 2,314 2,000
P2 Mean 84,20 11,124
95% Confidence Interval Lower Bound
53,32
for Mean
Upper Bound
115,08

5% Trimmed Mean 84,17

Median 79,00
Variance 618,700
Std. Deviation 24,874
Minimum 57
Maximum 112
Range 55
Interquartile Range 49,00
Skewness ,206 ,913
Kurtosis -2,768 2,000
P3 Mean 77,80 6,538
95% Confidence Interval Lower Bound
59,65
for Mean
Upper Bound
95,95

5% Trimmed Mean 77,89

Median 83,00
Variance 213,700
Std. Deviation 14,618
Minimum 60
Maximum 94
Range 34
Interquartile Range 28,00
Skewness -,342 ,913
Kurtosis -2,416 2,000

b. Analisis Analitik

1). Uji Normalitas

Tests of Normality
 67

Kolmogorov-Smirnov(a) Shapiro-Wilk
PERLAKU
A Statistic df Sig. Statistic df Sig.
KADAR K ,264 5 ,200(*) ,883 5 ,325
P1 ,257 5 ,200(*) ,829 5 ,137
P2 ,231 5 ,200(*) ,890 5 ,357
P3 ,239 5 ,200(*) ,911 5 ,474
* This is a lower bound of the true significance.
a Lilliefors Significance Correction

2). Uji One Way ANOVA

ANOVA

KADAR
Sum of
Squares df Mean Square F Sig.
Between Groups 2816,600 3 938,867 ,419 ,742
Within Groups 35831,200 16 2239,450
Total 38647,800 19

3. Kadar Kreatinin

Tabel 8. Kadar Kreatinin

Sampel Kontrol P1 P2 P3
A 0,38 0,15 0,49 0,36
B 0,52 0,38 0,33 0,37
C 0,36 0,28 0,33 0,31
D 0,40 0,41 0,42 0,37
E 0,46 0,34 0,36 0,43
Rata- 0,424 0,312 0,386 0,368
rata
 68

a. Analisis Deskriptif
Descriptives

PERLAKUA Statistic Std. Error

KADAR K Mean ,4240 ,02926
95% Lower Bound ,3428
Confidence Upper Bound
Interval for ,5052
Mean
5% Trimmed Mean ,4222
Median ,4000
Variance ,004
Std. Deviation ,06542
Minimum ,36
Maximum ,52
Range ,16
Interquartile Range ,1200
Skewness ,849 ,913
Kurtosis -,666 2,000
p1 Mean ,3120 ,04598
95% Lower Bound ,1843
Confidence Upper Bound
Interval for ,4397
Mean
5% Trimmed Mean ,3156
Median ,3400
Variance ,011
Std. Deviation ,10281
Minimum ,15
Maximum ,41
Range ,26
Interquartile Range ,1800
Skewness -1,153 ,913
Kurtosis ,996 2,000
p2 Mean ,3860 ,03076
95% Lower Bound ,3006
Confidence Upper Bound
Interval for ,4714
Mean
5% Trimmed Mean ,3833
Median ,3600
Variance ,005
Std. Deviation ,06877
 69

Minimum ,33
Maximum ,49
Range ,16
Interquartile Range ,1250
Skewness 1,019 ,913
Kurtosis -,265 2,000
p3 Mean ,3680 ,01908
95% Lower Bound ,3150
Confidence Upper Bound
Interval for ,4210
Mean
5% Trimmed Mean ,3678
Median ,3700
Variance ,002
Std. Deviation ,04266
Minimum ,31
Maximum ,43
Range ,12
Interquartile Range ,0650
Skewness ,229 ,913
Kurtosis 1,848 2,000

b. Analisis Analitik

1). Uji Normalitas

Tests of Normality

Kolmogorov-Smirnov(a) Shapiro-Wilk
PERLAK
UA Statistic df Sig. Statistic df Sig.
KADAR K ,243 5 ,200(*) ,922 5 ,544
p1 ,207 5 ,200(*) ,917 5 ,513
p2 ,247 5 ,200(*) ,867 5 ,254
p3 ,281 5 ,200(*) ,927 5 ,579
* This is a lower bound of the true significance.
a Lilliefors Significance Correction

2). Uji One Way ANOVA

ANOVA

KADAR
Sum of
Squares df Mean Square F Sig.
 70

Between Groups ,033 3 ,011 2,030 ,150

Within Groups ,086 16 ,005
Total ,118 19